CF101 + Placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Keratoconjunctivitis Sicca

Conditions

Keratoconjunctivitis Sicca

Trial Timeline

Jan 1, 2007 → May 1, 2009

NCT ID

NCT00349466

About CF101 + Placebo

CF101 + Placebo is a phase 2 stage product being developed by Can Fite Biopharma for Keratoconjunctivitis Sicca. The current trial status is completed. This product is registered under clinical trial identifier NCT00349466. Target conditions include Keratoconjunctivitis Sicca.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01905124	Phase 2	Withdrawn	Jan 1, 2019	Oct 1, 2019	Uveitis, Posterior
NCT00837291	Phase 2	Withdrawn	Nov 1, 2018	Jan 1, 2019	Osteoarthritis of the Knee
NCT01265667	Phase 2/3	Completed	Jul 1, 2011	May 1, 2015	Plaque Psoriasis
NCT00556894	Phase 2	Completed	Feb 1, 2008	Apr 1, 2009	Rheumatoid Arthritis
NCT00349466	Phase 2	Completed	Jan 1, 2007	May 1, 2009	Keratoconjunctivitis Sicca

Competing Products

15 competing products in Keratoconjunctivitis Sicca

See all competitors

Product	Company	Stage	Hype Score
FK506	Astellas Pharma	Phase 3	77
FK506 + placebo	Astellas Pharma	Phase 3	77
OTX-101 0.09%	Sun Pharmaceutical	Phase 3	77
OTX-101 0.05% + OTX-101 0.09% + Vehicle	Sun Pharmaceutical	Phase 2/3	65
cyclosporine + vehicle of OTX-101	Sun Pharmaceutical	Phase 3	77
INS365 Ophthalmic Solution	Merck	Phase 3	77
Pimecrolimus + Vehicle	Novartis	Phase 2	52
Cyclosporine A + Dexamethasone	Novartis	Approved	85
Rebamipide	Novartis	Phase 3	77
Rebamipide	Novartis	Phase 3	77
Tasocitinib + Tasocitinib + vehicle for Tasocitinib	Pfizer	Phase 2	51
Dupilumab	Regeneron Pharmaceuticals	Phase 2	51
R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + R348 Ophthalmic Solution, 1.0% + Placebo	Rigel Pharmaceuticals	Phase 1	25
R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + Placebo	Rigel Pharmaceuticals	Phase 2	44
CF101	Can Fite Biopharma	Phase 3	69

Other Products from Can Fite Biopharma

CF101Phase 3

Namodenoson + PlaceboPhase 3

piclidenoson + PlaceboPhase 3

CF101 1 mg + CF101 2 mg + Placebo + MTXPhase 3

CF101 2mg + CF101 3mg + Apremilast 30mg + Placebo Oral TabletPhase 3